

| | |
|--|--|
| Name | [REDACTED] |
| Role | other |
| Other role | [REDACTED], BHF |
| Location | England |
| CONFLICT | no |
| Notes | |
| Comments on individual sections of the ACD: | |
| SECTION 1 (APPRAISAL COMMITTEE'S PRELIMINARY RECOMMENDATIONS) | The BHF supports the committee's conclusion that dronedarone should not be recommended as a first-line anti-arrhythmic drug on the basis of current evidence. However, we believe that dronedarone should be available for use in people with either paroxysmal AF or persistent symptomatic AF that is not amenable to current therapies either because of side effects or lack of effect. |
| SECTION 2 (THE TECHNOLOGY) | |
| SECTION 3 (MANUFACTURER'S SUBMISSION) | |
| SECTION 4 (CONSIDERATION OF THE EVIDENCE) | We welcome the opportunity to respond to this consultation and to help shape NICE's recommendation on the use of dronedarone in the National Health Service. Atrial fibrillation (AF) is the most common type of significant abnormal heart rhythm and so it is important that a range of treatments are available. The BHF supports the committee's conclusion that dronedarone should not be recommended as a first-line anti-arrhythmic drug on the basis of current evidence. However, we believe that dronedarone should be available for use in people with either paroxysmal AF or persistent symptomatic AF that is not amenable to current therapies either because of side effects or lack of effect. A clear recommendation from NICE that dronedarone could be used in this context would help to expand the limited number of treatment options currently available and could bring significant quality of life improvements for those patients who find existing anti-arrhythmic drugs ineffective or intolerable. This should form part of a revised appraisal from NICE. If you have any queries about this response, please contact [REDACTED] on [REDACTED] or email [REDACTED]. |
| Section 5 (implementation) | |
| Section 6 (related NICE guidance) | |
| Section 7 (proposed date of review of guidance) | |
| Date | 1/26/2010 5:30:00 PM |